Current immunological approaches for management of allergic rhinitis and bronchial asthma

Srivastava, Deepti; Arora, Naveen; Singh, Bhanu

doi:10.1007/s00011-009-0033-7

Cited by 7 publications

(5 citation statements)

References 146 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allergic diseases are immunologic disorders, such as AR disease caused by a decreased CD4/ CD8 ratio and enhanced CD 8+ T cell activation. Immunotherapy acts by modifying CD4+ T-cell responses either by immune deviation, T-cell anergy and/or both 21 – 23 . Lee et al 24 showed that the CD4/CD8 ratio in the peripheral blood during acute asthma attacks was significantly higher than that of controls, with a significant reduction after treatment.…”

Section: Discussionmentioning

confidence: 99%

Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1/Th2 cytokines in mice with allergic rhinitis

Zhu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The present study aims to investigate the effect of immunotherapy in a mouse model of allergic rhinitis (AR) and to explore the possible molecular mechanisms of action. An animal model of AR was established by sensitization and challenge of BALB/c mice with house dust mite (HDM) extract. The mice were injected subcutaneously with HDM for immunotherapy. AR nasal symptoms were evaluated according to the frequencies of nose rubbing and sneezing and the degree of rhinorrhea. The nasal mucosa and lung tissue architecture and inflammatory status by histological analysis; the infiltration of eosinophils in nasal lavage fluid (NALF) of mice was observed by Diff-Quik stain; ELISA-based quantification of serum HDM-specific IgE and TH1/TH2 cytokine concentration; and flow cytometry detected the number of serum CD4+/CD8+ cells to evaluate the mechanism of immunotherapy. It was found that after immunotherapy, the AR symptom score was reduced, the number of eosinophils in NALF was reduced, and the infiltration of inflammatory cells and tissue damage in the nasal mucosa and lung tissue were alleviated. Immunotherapy can increase the number of CD4+ T cells in the peripheral blood, increase the ratio of CD4+/CD8+ cells, increase the expression of Th1 cytokines such as IL-2 and IFN-γ, reduce the expression of Th2 cytokines such as IL-4 and IL-5. The results showed that repeated intraperitoneal injection of crude extract of HDM for sensitization, followed by nasal drops can effectively construct a mouse model of AR, and subcutaneous injection of immunotherapy in mice can reduce allergic inflammation in model mice and improve the inflammatory infiltration of the nasal cavity in allergic rhinitis. Immunotherapy can reduce the expression of inflammatory factors in AR, improve Th1/Th2 balance, and may play a role in the treatment of AR by improving the function of immune cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1/Th2 cytokines in mice with allergic rhinitis

Zhu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Specific immunotherapy against allergic disorders requires frequent injections of allergen extract to slowly build up the maintenance dose [38]. Allergen specific immunotherapy with purified protein has shown potential but may cause anaphylactic reactions.…”

Section: Discussionmentioning

confidence: 99%

In silico Identification of IgE-Binding Epitopes of Osmotin Protein

2013

Self Cite

View full text Add to dashboard Cite

The identification of B-cell epitopes is an important step to study the antigen- antibody interactions for diagnosis and therapy. The present study aimed to identify B- cell epitopes of osmotin using bioinformatic tools and further modify these regions to study the allergenic property. B-cell epitopes were predicted based on amino acid physicochemical properties. Three single point mutations M1, M2, and M3 and a multiple point mutant (M123) were selected to disrupt the IgE binding. These mutants were cloned, expressed and proteins purified to homogeneity. The IgE binding of the purified proteins was evaluated by ELISA and ELISA inhibition with patients' sera. Three regions of osmotin M1 (57–70 aa), M2 (72–85 aa) and M3 (147–165 aa) were identified as potential antibody recognition sites using in silico tools. The sequence similarity search of the predicted epitopes of osmotin using Structural Database of Allergenic proteins (SDAP) showed similarity with known allergens from tomato, kiwifruit, bell pepper, apple, mountain cedar and cypress. Mutants M1, M2 and M3 showed up to 72%, 60% and 76% reduction, respectively in IgE binding whereas M123 showed up to 90% reduction with patients' sera. The immunoblot of M123 mutant showed 40% reduction in spot density as compared to osmotin. All mutants showed decreased inhibition potency with M123 exhibiting lowest potency of 32% with osmotin positive pooled patients' sera. The three B- cell epitopes of osmotin predicted by in silico method correlated with the experimental approach. The mutant M123 showed a reduction of 90% in IgE binding. The present method may be employed for prediction of B- cell epitopes of allergenic proteins.

show abstract

“…The early phase reaction occurs within a few minutes after allergen exposure, and the cells release mediators such as histamine and serotonin. The late phase reaction occurs hours after the early phase reaction in type I allergy; mediators such as inflammatory cytokines TNF-α, IL-4, IL-6, IL-8, and IL-13 are secreted from the cells [14][15][16]. β-Hexosaminidase, which is stored in the secretory granules of the mast cells, is released concomitantly with histamine when the mast cells are immunologically activated.…”

Section: Il-4mentioning

confidence: 99%

Inhibitory Effect of Acteoside Isolated fromCistanche tubulosaon Chemical Mediator Release and Inflammatory Cytokine Production by RBL-2H3 and KU812 Cells

et al. 2010

View full text Add to dashboard Cite

The immediate-type allergic reaction is involved in many allergic diseases such as asthma, allergic rhinitis, and sinusitis. In this study, we investigated the effect of acteoside extracted from CISTANCHE TUBULOSA (Schrenk) R. Wight on the basophilic cell-mediated allergic reaction. The effect of acteoside on β-hexosaminidase release and intracellular [Ca (2+)] I level from rat basophilic leukemia (RBL-2H3) cells was determined. Also, ELISA was used to determine the level of histamine, tumor necrosis factor (TNF)- α, and interleukin (IL)-4 on human basophilic (KU812) cells. The effect of acteoside on basophilic cell viability was determined using the 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide (MTT) assay. These results indicated that 0.1-10.0 µg/mL acteoside inhibits the release of β-hexosaminidase and [Ca (2+)] I influx from IgE-mediated RBL-2H3 cells. Moreover, acteoside inhibited histamine release, TNF- α, and IL-4 production in a dose-dependent manner from calcium ionophore A23187 plus phorbol 12-myristate 13-acetate (PMA) or compound 48/80-stimulated KU812 cells. Our findings provide evidence that acteoside inhibits basophilic cell-derived immediate-type and delayed-type allergic reactions. This is the first report describing antiallergic activity of acteoside extracted from CISTANCHE TUBULOSA on basophilic cells.

show abstract

Current immunological approaches for management of allergic rhinitis and bronchial asthma

Cited by 7 publications

References 146 publications

Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1/Th2 cytokines in mice with allergic rhinitis

Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1/Th2 cytokines in mice with allergic rhinitis

In silico Identification of IgE-Binding Epitopes of Osmotin Protein

Inhibitory Effect of Acteoside Isolated fromCistanche tubulosaon Chemical Mediator Release and Inflammatory Cytokine Production by RBL-2H3 and KU812 Cells

Contact Info

Product

Resources

About